During this briefing, panelists discussed factors policymakers must consider in order to support access to safe, effective, and affordable cell and gene therapies.
During this on-the-record briefing for reporters, Joe Grogan, Assistant to the President and Director of the Domestic Policy Council provided opening remarks and responded to questions from reporters. The question and answer period was moderated by William Pierce, Senior Director, APCO Worldwide.
During this congressional lunch briefing, analysts will outline the mechanisms of the Medicare Part D program under current law and discuss the potential implications of reforms put forward by Congress and the administration.
During this briefing, panelists will discuss components of policy proposals under consideration and explore evidence about their implications for the health care system.
During this webinar, analysts discussed the outstanding legislative and regulatory activities that Congress and the administration are likely to pursue before the end of the year.
During this webinar, panelists explored the relationship between patents, prices, and patient access.
There is no excerpt because this is a protected post.
During this briefing, panelists explained the mechanisms of biologic drugs, explore the impact of current regulations on the uptake of biosimilars, and discuss considerations for the biosimilars market in the United States.
The audience will come away with a better understanding of the origins of the rebate system, the actors responsible for negotiation, and the impact of rebates on prescription drug prices.
This webinar will focus on the first approach and will explore different perspectives on how increasing the number of generic and biosimilar options may affect the drug pricing market. Specifically, panelists discussed the main opportunities and challenges of the generic and biosimilar market, how past administrations have approached this issue, and how different stakeholders, including consumers, are impacted.
This exclusive reporter briefing featured FDA Commissioner Scott Gottlieb, M.D., followed by a panel of industry leaders and stakeholders responding to new drug pricing guidance.
The purpose of this briefing is to orient federal policymakers and stakeholders to the legislative and regulatory actions that state officials are perusing to address the rising cost of prescription drugs in Medicaid. Panelists will outline the rationale for these actions, detail the mechanisms of state policies, and describe opportunities to leverage flexibility within federal parameters.
The opioid addiction crisis has thrown a spotlight on the physical and behavioral health issues surrounding chronic pain. This briefing examined innovative non-pharmacologic models to address chronic pain, including among the military and veteran population and through state Medicaid and safety net programs.
This Alliance for Health Policy briefing discussed current issues in prescription drug affordability and innovation, focusing on potential policy and private-sector approaches to this complex issue.
This briefing featured presentations by our experts highlighting the trends in Medicare regarding prescription drug pricing, and panelists discussed an array of policy options to align drug prices with value through alternative payment models.
With biosimilar biological products moving from the lab to the marketplace, key policy and regulatory questions are being actively debated, with important implications for industry, patients, and the health care system.
Recent pharmaceutical innovations offer unprecedented possibilities for curing, treating, or preventing a range of diseases. However, patients, providers and payers alike have raised concerns about the affordability and sustainability of these drugs. As a response to price increases of both single-source and generic drugs, some stakeholders are calling for a move towards basing payments on value, and some payers and pharmaceutical manufacturers are exploring ways to base payments on outcomes. However, many challenges remain.
A top Federal Trade Commission official, along with key experts, met with reporters Dec. 15 to discuss the recent surge in health care consolidation; the driving forces behind this trend; and the implications for policymakers and enforcers.
In 2014, there were a total of 1,299 mergers and acquisitions in the health care sector – a record number, up from 1,035 the year before. This briefing will discussed the driving forces behind this recent increase in consolidation; the scope and extent of consolidation among doctors, hospitals and insurers; implications for consumers and other stakeholders; and the roles of the Department of Justice and the Federal Trade Commission.
Evidence shows that medication adherence—the extent to which a person takes medications as prescribed by their health care providers—is associated with improved health care outcomes for many costly chronic conditions, including heart disease, diabetes, and asthma. However, only 50% percent of Americans are estimated to take their medications as prescribed, and non-adherence is estimated to result in added direct and indirect costs to the healthcare system of over $300 billion per year. The challenges and policy questions surrounding medication adherence affect Medicare, Medicaid, and the private sector – and offer a window into broader questions surrounding the ability of our health care system to coordinate care, particularly for people with multiple chronic conditions. In this briefing, top experts from the public and private sectors explored key policy, practical, and research questions surrounding medication adherence and management of medications.